how novel agents may eliminate the need for transplant in all
Published 1 year ago • 86 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
1:56
incorporating novel agents for myelofibrosis in the pre- and post-transplant settings
-
3:02
novel transplant and post-transplant options in all
-
1:50
the value of moving novel agents into the frontline setting in all
-
0:47
novel agents being explored for the treatment of immune-mediated ttp
-
3:30
unmet needs in mf: managing anemia & improving the efficacy of first and second-line treatments
-
1:57
what is the survival rate for multiple myeloma?
-
3:35
challenges with implementing mesenchymal stem cells into practice
-
1:25
how the role of transplant in all is evolving with the introduction of novel immunotherapies
-
3:54
an insight into how novel agents are influencing survival outcomes in patients with mf
-
2:11
unmet needs in bone marrow failure syndromes & myeloid malignancies: characterization & novel agents
-
1:04
the changing role of autosct in the treatment of multiple myeloma in the era of novel agents
-
1:05
reprogramming leukemia cells into apcs as a novel therapeutic strategy for b-all
-
1:15
bringing novel agents to the frontline setting in myeloma
-
1:33
the need for novel therapeutic agents in myeloproliferative neoplasms
-
3:24
novel agents for the management of r/r myeloma
-
2:54
how novel agents & individualized treatment approaches are improving outcomes in patients with aml
-
2:06
how the mpn field has evolved over the years: novel agents, trials, and more
-
4:03
novel technologies in multiple myeloma and how these are changing the field
-
2:56
early vs. deferred transplantation in al amyloidosis
-
1:08
novel immunotherapies for multiple myeloma & other exciting developments
-
2:29
epitope editing enables the use of novel immunotherapies for aml